Asset
Tambiciclib
SELLAS Life Sciences Group Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04588922 | phase1_2 | recruiting | 2021-05-10 | 2026-12-30 | Sellas Life Sciences Group | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML |
FDA applications (0)
This company has no applications containing this asset.